1. Home
  2. TPVG vs LRMR Comparison

TPVG vs LRMR Comparison

Compare TPVG & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriplePoint Venture Growth BDC Corp.

TPVG

TriplePoint Venture Growth BDC Corp.

HOLD

Current Price

$5.51

Market Cap

240.8M

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$2.82

Market Cap

280.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPVG
LRMR
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.8M
280.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
TPVG
LRMR
Price
$5.51
$2.82
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$6.38
$16.50
AVG Volume (30 Days)
386.6K
976.0K
Earning Date
01-01-0001
04-14-2026
Dividend Yield
16.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.92
N/A
P/E Ratio
$6.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.24
$1.61
52 Week High
$8.20
$5.37

Technical Indicators

Market Signals
Indicator
TPVG
LRMR
Relative Strength Index (RSI) 31.80 34.26
Support Level $5.37 $1.77
Resistance Level $5.79 $3.27
Average True Range (ATR) 0.17 0.22
MACD -0.01 -0.04
Stochastic Oscillator 6.38 11.17

Price Performance

Historical Comparison
TPVG
LRMR

About TPVG TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: